Evidence / Henrotin et al. · 2019
Two doses of a bio-optimized turmeric extract in knee osteoarthritis
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Multicentre randomized, double-blind, placebo-controlled three-arm trial.
- Product relevance
- Ingredient research involving turmeric extracts or curcuminoids.
- Sample or population
- 150 people with knee osteoarthritis.
- Studied dose
- Four or six active capsules per day, each containing 46.67 mg of bio-optimized Curcuma longa rhizome extract, or placebo. The full paper reports the doses.
- Duration
- 90 days.
- Finding
- Patient-rated disease activity fell more in the extract groups. The cartilage biomarker did not differ between groups. A secondary pain measure favoured the extract, overall KOOS changes were comparable, and the high-dose group had more product-related adverse events than placebo.
- Limitations
- The co-primary outcomes did not agree. The pain result was secondary and the extract was formulation-specific.
- Study quality
- The outcomes, study design and limitations were reviewed. No formal risk-of-bias rating was assigned for this summary.
- Funding and disclosures
- Tilman SA funded recruitment, data collection and analysis. One author consulted for Tilman and chaired the company that made the biomarker assay. Another author was employed by Tilman.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Licensed product information
High-Potency Turmeric Extract · NPN 80143038
Source of (an) antioxidant(s)/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals.